These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24090634)

  • 1. Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study.
    Chang SC; Hung CT; Li SF; Lee HM; Chung YC; Pai LW; Yang SS
    J Formos Med Assoc; 2015 Sep; 114(9):829-34. PubMed ID: 24090634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
    Fujita N; Sugimoto R; Urawa N; Araki J; Mifuji R; Yamamoto M; Horiike S; Tanaka H; Iwasa M; Kobayashi Y; Adachi Y; Kaito M
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1886-93. PubMed ID: 17914965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hepatitis C virus infection in patients of northern India.
    Hazari S; Panda SK; Gupta SD; Batra Y; Singh R; Acharya SK
    J Gastroenterol Hepatol; 2004 Sep; 19(9):1058-65. PubMed ID: 15304125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
    Huang JF; Huang CF; Yu ML; Dai CY; Huang CI; Yeh ML; Hsieh MH; Yang JF; Hsieh MY; Lin ZY; Chen SC; Chuang WL
    J Gastroenterol Hepatol; 2011 Mar; 26(3):530-5. PubMed ID: 21332548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer.
    Su TH; Tseng TC; Liu CJ; Chou SW; Liu CH; Yang HC; Chen PJ; Chen DS; Chen CL; Kao JH
    Int J Cancer; 2020 Aug; 147(3):901-908. PubMed ID: 31853972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection.
    Su TH; Liu CJ; Tseng TC; Chou SW; Liu CH; Yang HC; Wu SJ; Chen PJ; Chen DS; Chen CL; Kao JH
    Aliment Pharmacol Ther; 2019 Feb; 49(3):331-339. PubMed ID: 30592071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
    Jian Wu Y; Shu Chen L; Gui Qiang W
    Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan.
    Lin SY; Chen TC; Lu PL; Lin CY; Lin WR; Yang YH; Chen YH
    BMC Infect Dis; 2014 Dec; 14():705. PubMed ID: 25523602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.
    Hsu CS; Kao JH; Chao YC; Lin HH; Fan YC; Huang CJ; Tsai PS
    Aliment Pharmacol Ther; 2013 Aug; 38(4):415-23. PubMed ID: 23802888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.
    Talal AH; LaFleur J; Hoop R; Pandya P; Martin P; Jacobson I; Han J; Korner EJ
    Aliment Pharmacol Ther; 2013 Feb; 37(4):473-81. PubMed ID: 23289640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic hepatitis C in southern Taiwan.
    Chuang WL; Yu ML; Dai CY; Chang WY
    Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
    Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
    Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism.
    Su TH; Yang HC; Tseng TC; Chou SW; Lin CH; Liu CH; Liu CJ; Chen CL; Kao JH
    Mov Disord; 2019 Dec; 34(12):1882-1890. PubMed ID: 31505068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
    Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
    Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.
    Raison CL; Broadwell SD; Borisov AS; Manatunga AK; Capuron L; Woolwine BJ; Jacobson IM; Nemeroff CB; Miller AH
    Brain Behav Immun; 2005 Jan; 19(1):23-7. PubMed ID: 15581735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.